Proteomics International Laboratories Ltd 2023 AR2
The report outlines Proteomics International Laboratories Ltd's strategic transition from research and development to commercialisation during the fiscal year ended June 30, 2023. A major milestone was the exclusive license agreement with Sonic Healthcare USA to commercialise the PromarkerD predictive test for diabetic kidney disease in the United States, supported by the approval of a CPT PLA reimbursement code. The company also made significant progress in its diagnostics pipeline, with prototype tests for endometriosis and oesophageal cancer demonstrating up to 90% accuracy in clinical studies. Additionally, the company successfully raised 8 million AUD to fund the scale-up of PromarkerD and further develop its diagnostic pipeline.
Company: Proteomics International Laboratories Ltd
Sector: Professional & technical services
Country: Australia
Year: 2023
Type: AR2
Pages: 45
Back to company
Proteomics International Laboratories Ltd
Annual Report
The report outlines Proteomics International Laboratories Ltd's strategic transition from research and development to commercialisation during the fiscal year ended June 30, 2023. A major milestone was the exclusive license agreement with Sonic Healthcare USA to commercialise the PromarkerD predictive test for diabetic kidney disease in the United States, supported by the approval of a CPT PLA reimbursement code. The company also made significant progress in its diagnostics pipeline, with prototype tests for endometriosis and oesophageal cancer demonstrating up to 90% accuracy in clinical studies. Additionally, the company successfully raised 8 million AUD to fund the scale-up of PromarkerD and further develop its diagnostic pipeline.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jul 1, 2022 - Jun 30, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management